AMSBIO has expanded its range of antibodies, biomarkers and assay kits related to free radicals (ROS and RNS), non-radical reactive derivatives (or oxidants) and antioxidants for researchers investigating the mechanism of oxidative stress.
It is widely recognized free radicals play a key role in physiological processes including protein phosphorylation as well as activation of transcriptional factors and immunity, but they need to be kept at a low level.
State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services
Press release - Appointments
Macomics Announces New Hires as it Expands its Macrophage-based Drug Discovery and Operations Teams
Edinburgh and Cambridge, UK, 18 July 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made three new appointments to its scientific and operations teams, to support growth and accelerate its R&D.
A screening tool developed in research led at the University of Strathclyde, UK could increase the number of tests on a solid tumour sample by up to 50 times.
The tool is designed for testing at scale the latest immunotherapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, which is effective against many haematological cancers but presents challenges when used to treat solid tumours.
A city centre building tailored to the commercialisation of life sciences has reached full capacity. The Biosphere opened its doors just three years ago, and is now home to more than 20 businesses, forming a vibrant and innovative life science cluster on Newcastle Helix.
New Board members will provide expert insight into ADME-Tox, biomarker, assay, cell and gene therapy, and immuno-oncology advances
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its new Scientific Advisory Board (SAB) comprised of experts in ADME-Tox, drug development, cell and gene therapy, immuno-oncology, and clinical diagnostics.
• Stevenage Bioscience Catalyst celebrates its 10th anniversary
• Events focus on the cutting-edge science of our occupier companies
• The campus is now at the heart of the biggest cluster for cell and gene therapy in Europe.
STEVENAGE 11th July 2022: Stevenage Bioscience Catalyst (SBC) is celebrating 10 years since it opened its doors to life sciences companies. A series of events was held on 6th July to celebrate the some of the breakthrough science being undertaken on campus including a science symposium, celebration lunch and scientific poster exhibition.